Tirzepatide: The First Dual GIP/GLP-1 Co-Agonist — Mechanism and Clinical Evidence

Tirzepatide's approval marks a genuine mechanistic departure from the established GLP-1 agonist paradigm. By simultaneously engaging both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, tirzepatide achieves weight reductions that exceed those of any prior pharmacological intervention — approaching, and in some sub-groups surpassing, outcomes associated with sleeve gastrectomy.

The Case for Dual Incretin Receptor Engagement

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin — secreted by K-cells in the duodenum and proximal jejunum, it accounts for roughly 50–70% of the postprandial incretin effect in healthy individuals. In type 2 diabetes, GIP's insulinotropic action becomes attenuated, leading to the historical — and now reassessed — view that GIP was an ineffective therapeutic target.

Tirzepatide's design challenges that assumption. The molecule is a 39-amino-acid single peptide with activity at both GIPR and GLP-1R, engineered on a GIP backbone with a C20 fatty diacid for once-weekly dosing. In preclinical models, GIPR agonism reduced body weight, improved insulin sensitivity, and showed additive effects when combined with GLP-1R agonism. The synergy appears to involve complementary central appetite circuits and peripheral adipose tissue effects — GIPR is expressed in adipocytes where its activation may modulate lipid metabolism and fat distribution.

Whether tirzepatide's superior efficacy over selective GLP-1 agonists is attributable to GIPR co-activation, higher effective GLP-1R engagement, or the two acting through distinct downstream pathways remains an active area of mechanistic investigation. The clinical evidence, however, is unambiguous.

SURMOUNT Programme: Efficacy Data

SURMOUNT-1 (n=2,539) enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one comorbidity, without diabetes. At 72 weeks, tirzepatide 15 mg produced a mean weight reduction of 20.9% from baseline, compared with 3.1% with placebo — a treatment difference of 17.8 percentage points (95% CI 16.9–18.7; p<0.001). The 10 mg dose achieved 19.5% and the 5 mg dose 15.0%.

The ≥20% weight loss response rate in the 15 mg group was 56.7% — meaning more than half of participants achieved a weight reduction that had previously been considered a bariatric surgery benchmark. Nearly one in five participants (18.3%) achieved ≥30% weight loss.

SURMOUNT-2 enrolled adults with T2DM and obesity. Even in this population — historically less responsive to weight-loss pharmacotherapy — tirzepatide 15 mg produced 13.4% mean weight reduction at 72 weeks versus 3.2% with placebo. HbA1c fell by 2.4 percentage points from a mean baseline of 8.0%, with 89.4% of participants achieving HbA1c <7.0%.

SURMOUNT-3 and SURMOUNT-4 examined tirzepatide in the context of intensive lifestyle intervention and as a weight maintenance therapy following acute caloric restriction, respectively. The maintenance trial is particularly notable: participants who lost ≥10% of body weight during a low-calorie diet run-in and then received tirzepatide for an additional 52 weeks maintained their weight loss and achieved a further 5.5% reduction, versus 14.8% weight regain in the placebo group.

FDA Approval Pathway and Indications

Tirzepatide received FDA approval as Mounjaro (5–15 mg SC weekly) for type 2 diabetes in May 2022. The obesity indication — marketed as Zepbound — was approved in November 2023 for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. Both formulations use identical drug substance and manufacturing; they differ in brand identity, labelling, and pricing.

The off-label prescribing of Mounjaro for obesity during the period between T2DM approval and Zepbound's obesity approval was widespread in clinical practice — reflecting prescriber confidence in the SURMOUNT data ahead of formal regulatory action. This has since normalised with Zepbound's approval.

Safety and Tolerability

Tirzepatide's tolerability profile is largely consistent with the broader GLP-1 agonist class. Nausea was reported in 31.0% of the 15 mg group in SURMOUNT-1 versus 11.7% with placebo; diarrhoea in 22.1% versus 9.0%. Importantly, the rate of treatment discontinuation due to adverse events was 6.3% — comparable to semaglutide and considered manageable with the standard 20-week dose escalation protocol beginning at 2.5 mg.

Gallbladder events (2.2%) and the class-level pancreatitis and medullary thyroid carcinoma concerns apply to tirzepatide as to all GLP-1R-containing agents. The GIPR component does not appear to introduce additional safety signals beyond those attributable to GLP-1R engagement — based on SURMOUNT data and post-approval pharmacovigilance to date.

Cardiovascular outcomes data for tirzepatide in an obesity-dedicated CVOT (SURPASS-CVOT) are expected; interim analyses have been promising. The drug's FDA obesity approval included a post-marketing requirement for a formal cardiovascular outcomes trial.

Position in the Treatment Algorithm

How does tirzepatide fit alongside semaglutide in clinical decision-making? No head-to-head RCT has been published, but indirect comparisons from network meta-analyses consistently rank tirzepatide 15 mg as the most efficacious approved pharmacological agent for weight reduction. For patients where maximum weight loss is the primary clinical goal — severe obesity, weight loss as prerequisite for surgical eligibility, or obesity-related MASH — tirzepatide 15 mg represents the current pharmacological ceiling.

Cost and insurance access remain practical determinants. Zepbound's list price is comparable to Wegovy; both face similar coverage variability under commercial insurance and exclusion under standard Medicare Part D.